Patrick Campbell

Investigators presented results of a study that analyzed renal function and markers of kidney damage in more than 1,000 patients in two randomized trials examining ertugliflozin.

A study analyzing the renal outcomes of the DECLARE-TIMI 58 trial were presented at ADA 2019 in San Francisco, CA.

A recent analysis of the BRIGHT trial examining renal function of insulin glargine 300u/mL versus insulin degludec 100u/mL was presented at ADA 2019.

After making the rounds at ADA 2019, Patrick Burgess, MD, discusses what he thinks is the most important discussion taking place at this year's conference and the biggest challenge facing diabetes patients.

An analysis of 7 trials examining cardiovascular outcomes of study drugs found that concomitant insulin use increased a patient’s risk of severe cardiovascular outcomes.

A meta-analysis of 3 real-world studies into the effectiveness of Abbot's FreeStyle Libre Flash Glucose Monitoring System at ADA 2019.

A recent study from ADA 2019 found that rates of depression, mental illness, and antidepressant use among diabetes patients have increased significantly from 2010 to 2016.

Investigators from Allegheny Health Network examined the impact of a multidisciplinary team approach on glycemic control in patients with diabetes in a primary care setting.

An analysis of results from the EXSCEL trial has suggested that exenatide with SGLT2 inhibitors may reduce major cardiovascular events and improve renal health.

A study into the impact of the timing of glucose blood readings has found that being 15 to 25 minutes late can almost double a patient's risk of hypoglycemia.

A decision for icosapent ethyl's sNDA is not expected to come from the FDA until September, but excitement surrounding the drug is at all-time high.

UNC professor of medicine discusses her thoughts on the largest challenges for physicians to overcome in the future of diabetes treatment.

Early initiation of GLP-1RA and SGLT2 in patients with T2D resulted in higher odds for long term HbA1C control and for lower CV risk factors.

Sue Kirkman, MD, professor of medicine at UNC Chapel Hill, discusses the results of a study she led that attempted to create a method of identifying what type of diabetes through EHR data.

John Buse, MD, professor of medicine at UNC Chapel Hill, discusses the results and implications of the PIONEER 7 trial.

Todd Hobbs, MD, chief medical officer of Novo Nordisk North America, discusses the results of PIONEER 4 at ADA 2019 in San Francisco, CA.

Todd Hobbs, MD, chief medical officer at Novo Nordisk North America, discusses what prompted Novo Nordisk to create oral semaglutide.

Todd Hobbs, MD, CMO of Novo Nordisk, discusses the findings of the PIONEER 2 study.

Investigators found that expansion states had a median of 4.3 fewer deaths per 100,000 residents than nonexpansion states.

Amarin announced the FDA had granted their sNDA for icosapent ethyl to reduce residual CV risk in patients with statin-managed LDL-C cholesterol.

A recent study found that dietary supplements for weight loss, energy, and muscle building were associated with a 3 times greater risk of severe medical events than vitamins.

Analyses of more than 2 million patients found that preterm and early births were associated with an increased risk of ischemic heart disease.

A recent study examines the association between new-onset atrial fibrillation and aortic valve replacements and transcatheter aortic valve implantations.

FDA has approved an sNDA for caftolozane/tezobactam for treatment of nosocomial pneumonia.

A study of more than 74,000 in China from 2006 to 2015 found that cardiovascular health scores are associated with subsequent risk of CVD events.

A recent study has found that consumption of coffee may not be as bad as previous studies have portrayed.

Investigators from St. Jude's Children Research Hospital presented the results of the phase 1 trial at ASCO 2019 in Chicago.

Investigators conducted an open-label, randomized, multi-center phase 2 study of VIT and vincristine with irinotecan without temozolomide that included 120 patients from 37 European centers.

A study presented at ASCO 2019 examined the differences between hospitalization cost and length of stay among pancreatic cancer patients based on location of the disease.

Preston Klassen, MD, executive vice president of Arena Pharmaceuticals, discusses potential uses for etrasimod outside of inflammatory bowel disease